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Abstract
Background—Several lines of evidence indicate that Regulator of G Protein Signaling 4 (RGS4)
contributes to schizophrenia vulnerability. RGS4 is one of a family of molecules that modulate
signaling via G-protein coupled receptors. Five genes encoding members of this family (RGS2,
RGS4, RGS5, RGS8 and RGS16) map to chromosome 1q23.3-1q31. Due to overlapping cellular
functions and chromosomal proximity, we hypothesized that multiple RGS genes may contribute to
schizophrenia severity and treatment responsiveness.
Methods—Subjects were 750 individuals with schizophrenia who participated in the Clinical
Antipsychotic Trials of Intervention Effectiveness (CATIE). Inferred ancestries were: 221 (30%)
‘Africa only’, 422 (56%) ‘Europe only’ and 107 (14%) ‘Other’. Fifty-nine single nucleotide
polymorphisms (SNPs) in or near the RGS5, RGS16, RGS8 and RGS2 genes were genotyped.
Multiple linear regression was used to analyze association of markers with Positive and Negative
Symptoms Scale (PANSS) total scores at baseline and throughout antipsychotic treatment.
Results—RGS5 marker rs10799902 was associated with altered baseline PANSS total score in both
the Africa only (P=0.0440) and Europe only (P=0.0143) strata, although neither association survived
multiple comparisons correction. A common five-marker haplotype of the RGS2 gene was associated
with more severe baseline PANSS total score in the Europe only strata (global P=0.0254; haplotype-
specific P=0.0196). In contrast to RGS4, none of the markers showed association with antipsychotic
treatment response.
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Conclusions—RGS2 and RGS5 genotypes predicted severity of baseline symptoms in
schizophrenia. Although these analyses are exploratory and replication is required, these data suggest
a possible role for multiple RGS proteins in schizophrenia.
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signaling; Cerebral cortex
1. Introduction
Schizophrenia is a neurodevelopmental disorder with a substantial genetic component
contributing to risk (Sullivan et al 2003). Independent functional and genetic studies indicate
that the regulator of G-protein signaling 4 (RGS4) gene is among a small group of promising
schizophrenia vulnerability genes (Harrison and Weinberger 2005; Norton et al 2006). The
initial focus on RGS4 arose from gene microarray and in situ hybridization studies showing
decreased levels of RGS4 mRNA across cortical regions (Mirnics et al 2001). Subsequent
analyses in postmortem cerebral cortex of patients with schizophrenia have confirmed
decreased levels of RGS4 transcript in superior temporal gyrus (Bowden et al 2007) and
decreased RGS4 protein in frontal cortex (Erdely et al 2006). A genetic association between
RGS4 and schizophrenia was detected initially in three different populations by Chowdari et
al (Chowdari et al 2002), and confirmed in five subsequent replication studies (Chen et al
2004; Fallin et al 2005; Morris et al 2004; Williams et al 2004; Zhang et al 2005). There have
been four reports of failures to replicate an association of RGS4 and schizophrenia (Kampman
et al 2006; Liu et al 2006; Rizig et al 2006; Sobell et al 2005). However, there also are recent
reports of association of certain intermediate phenotypes with RGS4 variants (Buckholtz et al
2007; Lipska et al 2006; Prasad et al 2005). Thus, RGS4 remains a strong schizophrenia
candidate gene, but its contributions must be considered in the context of heterogeneity (Levitt
et al 2006; Talkowski et al 2006). We recently described association of RGS4 variants with
both baseline schizophrenia symptom severity and antipsychotic treatment response in the
Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) sample (Campbell et al
2008).
RGS4 is one of more than 20 genes that encode RGS proteins, important regulatory components
of G-protein coupled receptor (GPCR) complexes. Antipsychotic medications act to modulate
GPCRs stimulated by dopamine, acetylcholine and serotonin. RGS proteins shorten the
duration of signaling via GPCRs by acting as GTPase activating proteins (GAPs), thereby
accelerating the deactivation of the heterotrimeric G protein following receptor activation.
Therefore, alterations in RGS availability or function could alter the effectiveness of
antipsychotic medications.
Based on homologous domain structure, the RGS proteins are categorized into families (Sierra
et al 2002; Xie and Palmer 2007). Genes encoding five of the ten “R4” family proteins lie
within a 30-Mb region of human chromosome 1q23.3-31, within a schizophrenia linkage region
identified in several genome-wide scans (Brzustowicz et al 2000; Ekelund et al 2004; Ekelund
et al 2001; Ekelund et al 2000; Gurling et al 2001; Hovatta et al 1999; Hwu et al 2003; Jang
et al 2007; Shaw et al 1998). Transcripts for each of these five chromosome 1q R4 family
proteins – RGS2, RGS4, RGS5, RGS8 and RGS16 – are abundantly expressed in the cerebral
cortex. Additionally, Rgs2 was found to be decreased in the prefrontal cortex of rats following
chronic treatment with the antipsychotic olanzapine (Fatemi et al 2006) and expression levels
of the Rgs2 and Rgs5 transcripts were found to be altered in the Drd1 receptor knockout mice
(Stanwood et al 2006). The confluence of these functional data with the chromosomal locations
of the five R4 family genes led us to hypothesize that other members of the R4 family, in
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addition to RGS4, may contribute to schizophrenia pathogenesis and differential antipsychotic
treatment response.
To test the hypotheses that RGS2, RGS5, RGS8 and RGS16 contribute to schizophrenia
symptom severity and antipsychotic treatment response, we performed an exploratory study
to determine association of genetic markers in or near these four genes with clinical traits
involved in the diagnosis of schizophrenia using the data generated by the CATIE trial
(Lieberman et al 2005; Stroup et al 2003). Our analyses show that baseline Positive and
Negative Symptoms Scale (PANSS) scores differed among RGS2 and RGS5 marker genotypes.
2. Experimental/ Materials and Methods
2.1. Subjects
The parent study has been described at length elsewhere (Lieberman et al 2005; Stroup et al
2003). Briefly, all subjects participated in CATIE (January 2001 to December 2004), a multi-
phase randomized controlled trial of antipsychotic medications involving 1,460 persons with
schizophrenia followed for up to 18 months. All subjects provided written informed consent
(including an additional consent for genetic studies), and the full study protocol was reviewed
by IRBs at the University of North Carolina and at participating study sites. Establishment of
schizophrenia diagnosis, inclusion criteria and exclusion criteria have been described
elsewhere (Sullivan et al 2006).
2.2 Phenotypes
Analyses were restricted to the total score of the Positive and Negative Symptoms Scale
(PANSS), a broadly accepted measure for reliably ascertaining severity of schizophrenia
symptoms (Kay et al 1987).
The CATIE treatment protocol is described elsewhere (Lieberman et al 2005; Stroup et al
2003). Briefly, patients with schizophrenia were randomly assigned to one of five antipsychotic
treatments in Phase 1. The five treatments in Phase 1 consisted of a first-generation
antipsychotic, perphenazine, and several second-generation (atypical) antipsychotics,
olanzapine, quetiaipine risperidone and ziprasidone (Lieberman et al 2005). The analyses
reported here are based on the 750 DNA samples available at the close of the CATIE trial.
The primary goal of the CATIE study was to compare the clinical effectiveness of a first-
generation antipsychotic, perphenazine, to four newer antipsychotics (Lieberman et al 2005).
Therefore, our analyses focused on comparing the response to perphenazine versus each of the
second-generation antipsychotics in phase 1 of CATIE. Change in PANSS total score from
baseline, measured longitudinally, was used to infer treatment response.
2.3. DNA Samples
High molecular weight DNA samples were obtained from all consenting subjects from cell
lines established via EBV transformation at the Rutgers University Cell and DNA Repository
(http://www.rucdr.org/quality_control.html). Sample DNA concentrations were quantified
and normalized via the use of Picogreen dsDNA Quantitation Kits (Molecular Probes, Eugene,
OR) (Sullivan et al 2006).
2.4. Genotyping and quality control
Selection of genotyping markers was performed with TAMAL
(http://neoref.ils.unc.edu/tamal) (Hemminger et al 2006) using dbSNP, HapMap, Perlegen and
UCSC data available mid-2005. SNPs were selected if they were more likely to lead to
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structural variation (i.e., a coding SNP) or had predicted functional significance (e.g., a SNP
in a highly conserved region or predicted promoter).
Genotyping was performed with TaqMan 5′ exonuclease assays (Livak 1999) as previously
described (Sullivan et al 2006). The overall no-call rate had median 0.67% (range 0.267–
2.80%). Genotyping was conducted blind to all clinical data. Automated allele calls were made
with SDS Data Collection software with all allele calls reviewed by an experienced operator
according to protocol. In order for a SNP to be released for analysis, we required that: (a) 46
duplicated samples per SNP were in agreement, (b) call rates for all plates exceeded 95%, and
(c) the clustering patterns were robust per review by an experienced technician. The assay for
RGS8 marker rs1287978 failed to meet these quality control criteria and was thus excluded
from the analyses.
2.5. Population stratification
Population stratification is a potential limitation of association studies (Sullivan et al 2001)
and is of particular concern in CATIE, given its explicit intent to ascertain a diverse, clinically
representative sample (Lieberman et al 2005; Stroup et al 2003). There are two preconditions
for population stratification to yield false positive results (Gorroochurn et al 2004; Heiman et
al 2004). Because population stratification as a confounder exists only if the phenotypic
distribution and the marker allele frequency differ across ancestral strata, we can determine
the impact of stratification by measuring the marker and disease frequency and predict the
extent of stratification. If there is substantial evidence that population substructure exists in the
overall CATIE sample for the markers studied here, we default to stratified analysis. CATIE
subjects were allowed to select multiple racial categories (White, Black/African-American,
American Indian or Alaska native, Asian, Native Hawaiian or Pacific Islander, or Other) and
were also asked if they were Hispanic or Latino. Inferred ancestry was defined as “Africa only”
if a subject endorsed Black/African-American only, ”Europe only” if a subject endorsed White
only, and “Other” if any other racial category was endorsed.
2.6. Statistical analysis
Data management and statistical analyses were performed using SAS version 9.1.3 (SAS
Institute Inc). For baseline PANSS score analyses, analysis of covariance (ANCOVA) models
were used to test for genotypic association, with adjustment for ancestry, sex, and age. In
CATIE, the PANSS was administered at baseline and at multiple time points during
antipsychotic treatment. Longitudinal analyses were performed using multiple linear
regression with generalized estimating equation (GEE) models (Zeger et al 1988), which allow
adjustment for the non-independence of PANSS scores on the same individual over multiple
time-points, used to test genotype X treatment interaction effects across phase 1. Significant
interactions represent altered PANSS score throughout the treatment period when comparing
perphenazine response to olanzapine, quetiapine, risperidone and ziprasidone responses. These
models included the covariates of baseline PANSS score, treatment, sex, and age. Haplotype
association tests for baseline PANSS score were performed using the program HAPLO.STAT
(http://www.mayo.edu/statgen), which utilizes a weighting scheme based on EM derived
haplotype frequency estimates and weights every haplotype rather than assigning a ‘most
likely’ haplotype to an individual. An additive mode of inheritance assumption was made for
all genotypic and haplotypic tests of association. HaploView (version 3.2) (Barrett et al
2005) was used to calculate tests of Hardy-Weinberg Equilibrium (HWE), and |D’| and r2
estimates to assess linkage disequilibrium.
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The sample for this report is 750 CATIE subjects who provided DNA samples. Details on the
sample are provided in Table 1.
3.2. Stratification by ancestry
Supplementary Table 1 contains Hardy-Weinberg Equilibrium (HWE) results for the SNPs
genotyped. The allele frequencies for many of the genotyped SNPs were divergent from HWE
in the combined sample but absent when analyzed separately by ancestry, suggesting
population stratification. We therefore defaulted to analyzing the data by ancestral strata.
3.3. Regional map and linkage disequilibrium (LD)
Figure 1 depicts the 30-Mb region of chromosome 1q23.3-1q31 including RGS4, RGS5,
RGS16, RGS8 and RGS2 in the 422-sample Europe only strata. A total of 67 markers (including
8 markers genotyped in RGS4) (Campbell et al 2008) were genotyped in the CATIE sample.
The RGS4 5′ markers associated with baseline schizophrenia severity and antipsychotic
treatment response (rs951439, rs2661319 and rs2842030) (Campbell et al 2008) were not in
LD with the remaining markers genotyped in the R4 family. In contrast, the RGS4 3′ markers
showed high levels of LD with the nearest twelve markers of the neighboring RGS5 gene
(approximately 32-kb) (Figure 1). Therefore, associations of the RGS5 gene must be interpreted
in the context of its LD with RGS4. Thirteen additional markers near the 61-kb RGS5 gene
defined a separate 39-kb LD block (Figure 1). Thirteen markers genotyped near the 6-kb
RGS16 gene defined two LD blocks of approximately 15- and 2-kb (Figure 1). Twelve markers
spanning the 28-kb RGS8 gene defined two LD blocks of approximately 10- and 4-kb (Figure
1). Nine genotyped markers near the 3-kb RGS2 gene defined two LD blocks of approximately
7-kb each (Figure 1). The LD structures were similar in the African and European ancestry
strata (Supplementary Table 2).
3.4 Genotype association with baseline PANSS total score
RGS5 intron 1 marker rs10799902 demonstrated significant genotypic association with
baseline PANSS total score in both the African and European ancestry strata (Table 2). The
association did not survive Bonferroni correction in either strata (Table 2). In both ancestral
strata, individuals of rs10799902 genotype A/A displayed higher baseline PANSS total scores
than individuals with genotype G/G (Table 2). Of the 25 markers genotyped near the RGS5
gene, six showed association in the Africa only strata and two displayed association in the
Europe only strata; however, none of these associations survived Bonferroni correction for
multiple comparisons (Table 2; Supplementary Table 3). Of the seven RGS5 markers with
significant uncorrected differences in baseline PANSS total score, only rs2456899 has a high
degree of LD with markers in RGS4 (r2 with RGS4 marker rs2063142 = 0.458); however
rs2456899 is not in LD (r2<0.001) with the RGS4 markers that showed association with baseline
PANSS total score in our previous report (rs2661319 and rs2842030) (Campbell et al, 2008)
(Supplementary Table 1). Haplotype-based analysis of a 6-marker LD block in the Africa only
strata (rs4657248-rs4657251-rs10799902-rs7513108-rs2999967-rs2999965) including 3
markers with uncorrected association (rs10799902, rs2999967 and rs2999965) failed to show
significant global association (P=0.33).
None of the 25 markers genotyped near the RGS16 and RGS8 genes demonstrated significant
uncorrected genotypic differences in baseline PANSS total score (Supplementary Table 3).
Of the 9 markers genotyped near RGS2, uncorrected significant association was observed for
five markers in the Europe only strata and one marker in the Africa only strata (Table 2).
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However, none of these differences survived correction for multiple comparisons. In a 5-
marker LD block spanning the 3′ end of the RGS2 gene (rs2746073-rs4606-rs3767488-
rs1819741-rs10801156; r2>0.61), four markers revealed uncorrected differences in baseline
PANSS total score in the Europe only sample: rs2746073 (P=0.0331), rs4606 (P=0.0261),
rs3767488 (P=0.0325) and rs10801156 (P=0.0355) (Table 2). Haplotype-based analyses of
this 5-marker LD block revealed a significant global association (P=0.0254) in the Europe only
strata. There were only two haplotypes with frequency >1%. Haplotype A-G-G-C-C
(frequency=0.257) was associated with significantly lower PANSS total score (P=0.0093);
haplotype T-C-A-T-A (frequency=0.732) was associated with significantly higher baseline
PANSS total score (P=0.0196) (Table 3). Permutation analyses confirmed the significant
global haplotype association (P=0.030), the A-G-G-C-C association with lower PANSS total
score (P=0.015) and the T-C-A-T-A association with higher PANSS total score (P=0.024).
3.5. Genotype association with antipsychotic treatment response
Using GEE models to include all available longitudinal data, SNP by treatment analyses for
PANSS total indicated that, after correction for multiple comparisons, none of the genotype
markers exhibited significant association (Supplementary Table 4). Of the 59 genotyped
markers, we observed uncorrected significant differences for 3 markers in the Africa only
sample and 5 markers in the Europe only sample (Supplementary Table 4). Notably, four
consecutive markers in RGS8, all in LD (r2>0.5), demonstrated uncorrected evidence for SNP
by treatment interactions in the Europe only strata: rs3845459 (P=0.0291), rs10489965
(P=0.0358), rs1287978 (P=0.0517) and rs4652741 (P=0.0317). None of these markers show
a main effect of genotype on treatment response in a longitudinal setting (Supplementary Table
4).
Tests of the main effect of genotype on treatment response revealed uncorrected significant
differences for one marker in the Africa only and two markers in the Europe only strata
(Supplementary Table 4). Notably, the two markers with uncorrected evidence for a main effect
of genotype in the Europe only strata were consecutive markers in RGS2: rs2179652
(P=0.0446) and rs1890397 (P=0.0486) (Supplementary Table 4). None of these differences
survive Bonferroni correction for multiple comparisons.
4. Discussion
The present exploratory study revealed an association of genetic variants in the RGS5 gene and
a haplotype block in the RGS2 gene with baseline schizophrenia symptom severity. Thus, along
with another R4 family member RGS4, RGS2 and RGS5 may contribute to schizophrenia
symptom severity. In contrast to RGS4, none of the other R4 family members tested here
contributed to differential antipsychotic treatment response in the CATIE Phase 1.
The results of this study should be interpreted cautiously as none of the uncorrected single
marker associations survive correction for multiple comparisons. A limitation of this study was
the necessity to stratify by ethnicity to account for population stratification, and thus decrease
the sample size significantly.
The region of chromosome 1q harboring the R4 gene family may include multiple genes that
contribute to schizophrenia vulnerability. Several schizophrenia genome-wide linkage scans
have identified peaks in the chromosome 1q21-42 region (Brzustowicz et al 2000; Ekelund et
al 2004; Ekelund et al 2001; Ekelund et al 2000; Gurling et al 2001; Hovatta et al 1999; Hwu
et al 2003; Jang et al 2007; Shaw et al 1998). However, the location of the peak varies across
linkage studies: linkage evidence has been reported for chromosome 1q21-24.2 (near the
RGS4 and RGS5 genes) (Brzustowicz et al 2000; Gurling et al 2001; Hwu et al 2003; Shaw et
al 1998), chromosome 1q31.1-32.2 (near the RGS2 gene) (Ekelund et al 2001; Hovatta et al
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1999; Jang et al 2007; Shaw et al 1998) and chromosome 1q42 (near the DISC1 gene) (Ekelund
et al 2004; Ekelund et al 2000; Hwu et al 2003). RGS4 and DISC1 are among the most promising
schizophrenia candidate genes with multiple replications of the original positive association;
however, multiple reports failing to replicate association with schizophrenia have been reported
for both genes (Levitt et al 2006; Norton et al 2006; Talkowski et al 2006). At chromosome
1q21-23, recent positional candidate approaches have identified variants associated with
schizophrenia within both the CAPON (Brzustowicz et al 2004) and UHMK1 genes (Puri et al
2007). Association of CAPON was replicated in one sample (Zheng et al 2005), but failed to
replicate in a different sample (Puri et al 2006). Near the chromosome 1q31-32 linkage peak,
a single whole genome association study identified convincing evidence for association of
markers in the PLXNA2 gene in the discovery sample and four replication samples (Mah et al
2006); however, an independent attempt to replicate these findings failed to confirm the
association (Fujii et al 2007). Perhaps as can be expected for a clinically heterogeneous
disorder, although several promising schizophrenia candidate genes have been identified in the
chromosome 1q21-42 region, conflicting results for each gene have been reported. The
associations of RGS2 and RGS5 variants with baseline PANSS total scores, along with previous
associations of RGS4 variants with schizophrenia, suggest that multiple RGS proteins may
modulate the function of circuits implicated in schizophrenia.
In conclusion, the data presented here suggest that variants in two genes, RGS5 and RGS2, may
influence the severity of schizophrenia symptoms. It is also conceivable that the baseline
differences in the schizophrenia symptoms may reflect differential antipsychotic treatment
responses to medications that patients had received prior to entry into CATIE Phase 1. In this
context, it could be speculated that the RGS proteins are associated with an aspect of illness
severity that influences patients’ capacity to respond to antipsychotic drug treatment. Further
experiments with a much larger sample collection will be required to test these hypotheses. As
with all genetic association studies, precise replication is required in order to determine whether
these findings are sample-specific or whether they apply more generally to clinical samples of
individuals with schizophrenia (Sullivan 2007).
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Genomic region of chromosome 1q23.3-31 including RGS4, RGS5, RGS16, RGS8 and
RGS2. All five genes are included in a 30-Mb region; the chromosome is drawn to scale. LD
blocks (Haploview, version 3.1.2) for the 422-sample Europe only sample are designated.
Arrows indicate boundaries of markers near indicated genes. Pairwise r2 values (X 100) are
indicated for the CATIE Europe only sample. D′ and r2 values for the Africa only and Europe
only ethnic strata are listed in Supplementary Table 2.
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